Ethris has joined the cmRNAbone consortium of 11 European partners working to develop chemically modified RNAs and a specific vector delivery system as a novel bone regenerative therapy for trauma and osteoporosis patients. The partners will receive EUR 6.3 million funding from the European Union’s Horizon 2020 Framework Program.

GO TO PARTNER WEBSITE